{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-389836","form_type":"8-K","ticker":"QTTB","cik":"0001661998","company_name":"Q32 Bio Inc.","filed_at":"2026-09-14T11:15:30+00:00","discovered_at":"2026-09-14T11:20:01.682430+00:00","generated_at":"2026-09-14T11:20:27.438507+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Q32 Bio names José Trevejo CMO and Ellie Hershberger CDO; bempikibart registration program targeted H1 2027","bullets":["José Trevejo, M.D., Ph.D. named CMO; ex-CMO at Tarsus (helped win FDA approval of XDEMVY for Demodex blepharitis) and ex-CDO at Rocket Pharmaceuticals.","Ellie Hershberger, Pharm.D. named CDO; ex-CDO at Adagio/Invivyd, led antibody from IND-enabling to Phase 3 and helped raise ~$356M in IPO gross proceeds.","Company targets advancing bempikibart into registration-directed program for severe or very severe alopecia areata in first half of 2027.","Q32 Bio says SIGNAL-AA Part B showed meaningful hair regrowth, early durability off-drug, and generally well-tolerated safety profile for bempikibart."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-389836","json":"https://secwatch.observer/filing/0001193125-26-389836.json","markdown":"https://secwatch.observer/filing/0001193125-26-389836.md","text":"https://secwatch.observer/filing/0001193125-26-389836.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661998/000119312526389836/0001193125-26-389836-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661998/000119312526389836/d158730d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-14T11:20:27.438507+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}